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 Both proteolysis-inducing factor (PIF) and angiotensin II (Ang II) directly 
induce protein degradation in skeletal muscle through an increase in level of the 
ubiquitin-proteasome pathway, which involves activation of the nuclear 
transcription factor NF-B.  The role of the serine / threonine kinase, Akt / PKB, 
in this process has been studied in murine myotubes expressing a dominant 
negative mutant of Akt (DNAkt), or a constitutively active Akt construct (Myr Akt).  
Both PIF and Ang II induced protein degradation in wild-type myotubes with a 
parabolic dose-response curve, while myotubes containing Myr Akt showed an 
enhanced response to both agents, and those containing DNAkt showed a 
reduced protein degradation.  A similar effect was observed on the induction of 
chymotrypsin-like enzyme activity, as a measure of the 20S proteasome 
functional activity as well as expression of 20S proteasome -subunits and the 
19S subunit p42, as well as the loss of myosin.  PIF induced phosphorylation of 
Akt at Ser473, and this was attenuated by the phosphoinositide 3-kinase (PI3-K) 
inhibitor LY294002, suggesting that it was due to activation of PI3-K.  PIF 
induced an increase in inhibitor-B (I-B) phosphorylation, a reciprocal decrease 
in cellular levels of I-B, and an increased nuclear accumulation of NF-B, and 
these effects were also attenuated by LY294002.  These results suggest that PIF 
induces activation of Akt through induction of PI3-K activity, and that this 
provides an alternative route for an increased nuclear binding of NF-B, through 
phosphorylation and subsequent degradation of I-B, resulting in an increased 
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protein degradation.  Thus Akt may play a role in protein degradation in the 
presence of catabolic stimuli in addition to its role in protein synthesis in muscle. 
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INTRODUCTION 
 The ubiquitin-proteasome proteolytic pathway has been shown to play a 
major role in muscle wasting in starvation, sepsis, metabolic acidosis, diabetes, 
weightlessness, severe trauma, denervation and cancer cachexia [1].  This 
pathway can be activated by a number of factors, including proteolysis-inducing 
factor (PIF), a sulphated glycoprotein produced by cachexia-inducing tumours 
[2], cytokines such as tumour necrosis factor- (TNF-) and interferon- (IFN-) 
[3], angiotensin II (Ang II) [4] and glucocorticoids [5], while disuse atrophy results 
from an increase in oxidative stress [6].  Induction of protein degradation through 
the ubiquitin-proteasome pathway by PIF [7], TNF- [8], Ang II [9] and reactive-
oxygen species (ROS) [10] involves activation of the nuclear transcription factor 
NF-B.  Activation of NF-B through muscle-specific transgenic expression of 
activated IB kinase  (IKK) has been shown [11] to induce profound muscle 
wasting with an increase in mRNA levels for the C2 and C9 subunits of the 
proteasome, as well as for MuRF1, a muscle-specific E3 ligase, which is 
upregulated during atrophy, and loss of which provides partial protection of 
muscle loss after denervation [12].  Interestingly mRNA levels for another E3 
ligase atrogin-1 / MAFbx, also implicated in muscle protein degradation [13], 
were normal, as were those for ubiquitin and the ubiquitin-conjugating enzyme 
E214k.  Induction of atrogin-1 has been shown to be mediated by the Forkhead 
box O (Foxo) class of transcription factors [14]. 
 Studies on the intracellular signal transduction pathways involved in 
activation of NF-B have mainly been performed using PIF and Ang II in murine 
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myotubes.  Both PIF [15] and Ang II [9] have been shown to activate protein 
kinase C (PKC), and this was shown to be important in the induction of 
proteasome expression and NF-B activation, since myotubes transfected with a 
dominant-negative PKC, showed no increase in nuclear binding of NF-B in 
response to PIF and no increase in proteasome expression [15].  In addition, 
calphostin C, a highly specific inhibitor of PKC attenuated phosphorylation and 
degradation of IB by both Ang II [9] and by 15-hydroxyeicosatetraenoic acid 
(15-HETE) [16] considered to be an essential signalling molecule in proteasome 
upregulation by PIF [17].  These effects of PKC are thought to be mediated by 
phosphorylation and activation of the upstream regulator kinase IKK [18]. 
 An alternative pathway for phosphorylation of IKK, which is utilized by both 
TNF- [19] and platelet derived growth factor (PDGF) [20], involves the serine / 
threonine kinase Akt / PKB.  Oxidative stress has also been shown to activate 
Akt, by increasing phosphorylation [21].  Activation of Akt by growth factor and 
cytokine treatment generally occurs via the phosphatidylinositide 3-kinase (PI3-
K) pathway.  However, IGF-1 induces hypertrophy by stimulating the PI3-K / Akt 
pathway [22], and constitutive activation of Akt induces rapid and significant 
skeletal muscle hypertrophy [23].  The hypertrophic effect is due to stimulation of 
translation, via regulation of glycogen synthelase kinase GSK and mTOR kinases 
[24].  Akt overexpression inhibits the Foxo transcription factors by increasing 
phosphorylation, inhibiting atrogin-1 expression [14]. 
 In order to investigate the role, if any, of Akt in protein degradation we 
have transfected myotubes with plasmids expressing a dominant-negative 
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mutant of Akt, as well as a constitutively active Akt construct, and studied the 
effect on both protein degradation and proteasome activity in response to both 
PIF and Ang II.  Using an inhibitor of PI3-K the effects have been associated with 
the state of activation of NF-B. 
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MATERIALS AND METHODS 
 Foetal calf serum (FCS), horse serum (HS) and Dulbecco’s modified 
Eagle’s medium (DMEM) were purchased from Life Technologies (Paisley, UK).  
Mouse monoclonal antibody to I-B was purchased from Biomol Research 
Laboratories Inc. (PA, USA) and to HA.11 from Cambridge Bioscience Ltd 
(Cambridge, UK).  Mouse monoclonal antibodies to 20S proteasome -subunits 
and p42 were from Affiniti Research Products (Exeter, UK).  Mouse monoclonal 
antibody to myosin heavy chain was from Novocastra (Newcastle, UK).  Rabbit 
polyclonal antisera to phosphorylated I-B was from Merck Eurolab Ltd. 
(Leicestershire, UK) and polyclonal antisera to Akt that detects endogenous Akt1, 
Akt2 and Akt3 proteins, together with mouse monoclonal antibody to phospho-
Akt (Ser 473) were from New England Biolabs (Herts, UK).  Rabbit polyclonal 
antisera to mouse actin was from Sigma-Aldridge (Dorset, UK).  Peroxidase-
conjugated rabbit anti-mouse antibody and peroxidase-conjugated goat anti-
rabbit antibody were purchased from Dako Ltd. (Cambridge, UK).  Hybond A 
nitrocellulose membranes, L-[2, 6-3H] phenylalanine (sp. act. 2.07 TBq/mmole) 
and enhanced chemiluminescence (ECL) development kits were from Amersham 
Bioscience UK Ltd. (Bucks, UK).  LY294002 was purchased from Calbiochem 
(through CN Biosciences, UK, Nottingham, UK).  Lactacystin was purchased 
from Affiniti Research Products (Exeter, UK) and the chymotrypsin substrate 
succinyl-Leu-Leu-Val-7-amino-4-methylcoumarin (AMC) from Sigma-Aldridge 
(Dorset, UK).  Expression vectors (pcDNA) encoding mouse Akt proteins fused 
in-frame to the hemagglutinin (HA) epitope [23] were kindly supplied by Dr. 
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Kenneth Walsh (Tufts University, School of Medicine, Boston, USA).  Catch and 
Release V.2.0 reversible immunoprecipitation system was purchased from 
Upstate (Milton Keynes, Bucks, UK).  This system was used to 
immunoprecipitate Akt from transfected myotubes using the HA.11 monoclonal 
antibody according to the manufacturer’s instructions. 
 
Cell culture The C2C12 myoblast cell line was grown in DMEM supplemented 
with 10% FCS plus 1% penicillin and streptomycin under an atmosphere of 5% 
CO2 in air at 37°C.  Cells were transfected with the plasmid DNA in OPTI-
medium using Lipofect Amine (Gibco) at a ratio of 1:5 and incubated at 37°C for 
18-48h prior to testing for transgene expression.  Cells were passaged (1:10) in 
fresh growth medium for 24h and selected for growth in neomycin for 48-72h.  
Myotubes were formed by allowing confluent cultures of myoblasts to fuse in 
DMEM containing 2% HS over a 5-7 day period, with changes of medium every 2 
days. 
 
Purification of PIF PIF was purified from solid MAC16 tumours from mice with 
weight loss between 20 and 25%.  The tumour homogenate was precipitated with 
ammonium sulphate (40% w/v), and the supernatant subjected to 
chromatography using a monoclonal antibody immobilized to a protein A matrix 
as described [25].  The immunogenic fractions were concentrated and used for 
studies without further purification, since the major contaminant was albumin 
[25]. 
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Measurement of protein degradation The method for the measurement of 
protein degradation in murine myotubes has been described [2].  Briefly 
myotubes were prelabeled for 24h with L-[2, 6-3H] phenylalanine and were 
washed extensively prior to experimentation.  Protein degradation was 
determined by the release of L-[2, 6-3H] phenylalanine into the medium after 24h 
incubation with various concentrations of PIF, Ang I or Ang II as depicted in the 
figure legends in the absence or presence of inhibitors added 2h before the 
agonists.  Cold phenylalanine was added to prevent reincorporation of 
radioactivity into cells. 
 
Measurement of proteasome ‘chymotrypsin-like’ activity ‘Chymotrypsin-like’ 
enzyme activity was determined fluorimetrically by the method of Orino et al [26] 
as previously described [7].  Myotubes were washed with ice-cold phosphate 
buffered saline (PBS) and sonicated in 20mM Tris HCl, pH 7.5, 2mM ATP, 5mM 
MgCl2 and 1mM dithiothreitol at 4C.  The supernatant formed by centrifugation 
at 18,000g for 10min was used to measure ‘chymotrypsin-like’ enzyme activity by 
the release of aminomethyl coumarin (AMC) from the fluorogenic peptide 
succinyl-LLVY-AMC (0.1mM).  Activity was measured in the presence and 
absence of the specific proteasome inhibitor lactacystin (10M).  Only lactacystin 
suppressible activity was considered to be proteasome specific. 
 
Measurement of protein synthesis Myotubes were formed in 6-well 
multiwell dishes, and were supplemented with DMEM without HS and phenol red 
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18h prior to experimentation.  PIF was added at the concentrations indicated 
followed by 2l L-[2, 6-3H] phenylalanine (sp.act. 1.96TBq / mmol) in 8l sterile 
PBS and the plates were incubated for 4h at 37C under an atmosphere of 5% 
CO2 in air.  The reaction was arrested by washing three-times with 1ml ice-cold 
sterile PBS.  Following removal of the PBS 1ml ice-cold 0.2M perchloric acid was 
added and the plates were kept at 4C for 20min.  The perchloric acid was 
substituted with 1ml 0.3M NaOH per well and incubation was continued for 30min 
at 4C, followed by a further incubation at 37C for a further 20min.  The NaOH 
extract was removed and combined with a further 1ml wash of each well and 
0.5ml 0.2M perchloric acid was added and left on ice for 20min.  The extract was 
then centrifuged at 700g for 5min at 4C and the protein-containing pellet was 
dissolved in 1ml of 0.3M NaOH and 0.5ml of the solution was counted for 
radioactivity after mixing with 8ml Ultima Gold XR scintillation fluid. 
 
Western blot analysis Cytoplasmic proteins (5-15g), obtained from the 
above assay, were also used for Western blotting I-B for 20S proteasome -
subunits, p42, myosin, and phospho-I-B, while the total cell extract (30g 
protein) was used for Western blotting for Akt and phospho-Akt.  5g of 
immunoprecipitated protein using HA.11 was used for immunoblotting for Akt.  
Proteins were resolved on 12% sodium dodecylsulphate: polyacrylamide gels 
and transferred to HybondTM nitrocellulose membrane.  Membranes were 
blocked with 5% Marvel in PBS at 4C overnight.  The primary antibodies were 
used at a dilution of 1:1000, except for -tubulin which was used at 1:40, and the 
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secondary antibodies were used at a dilution of 1:2000.  Incubation was carried 
out for 2h at room temperature, and development was by ECL.  Total cellular 
actin was used as a loading control.  Blots were scanned by a densitometer to 
quantitate differences. 
 
Electrophoresis mobility shift assay (EMSA) DNA binding proteins were 
extracted from myotubes by the method of Andrews and Faller [27], which 
utilizes hypotonic lysis followed by high salt extraction of nuclei.  The EMSA 
binding assay was carried out using a Panomics EMSA ‘gel shift’ kit according to 
the manufacturer’s instructions. 
 
Statistical analysis Differences in means between groups was determined by 
one-way ANOVA followed by Tukey-Kramer Multiple Comparison Test.  All 
experiments were repeated at least 3 times on separate occasions and the 
results shown are an average of the repeats. 
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RESULTS 
 Murine myotubes were transfected with plasmids encoding a dominant 
negative Akt (DNAkt) in which the two activating amino acid residues threonine 
308 and serine 473 were changed to alanine [24], or a constitutively active Akt 
construct (Myr Akt), containing the c-src myristoylation sequence fused in-frame 
to the N-terminus of the HA-Akt (wild-type) coding sequence.  
Immunoprecipitation of cell lysates with anti-HA antibody, followed by Western 
blotting for Akt confirmed expression of both dominant negative and constitutively 
active Akt (Fig. 1A).  When the myotubes were incubated with PIF protein 
degradation was increased with a maximal effect at 4.2nM as previously reported 
[15, 16] (Fig. 1B).  Myotubes containing Myr Akt showed enhanced protein 
degradation over wild-type at all concentrations of PIF, while those containing 
DNAkt showed a reduced protein degradation at the maximum activating 
concentration of PIF.  A similar result was obtained with both Ang I (Fig. 1C) and 
Ang II (Fig. 1D).  The effect of Ang I was attenuated by co-treatment with the 
ACE inhibitor imidaprilat (50M), suggesting that the stimulation of protein 
degradation was due to formation of Ang II.  Both Ang I and Ang II induced 
protein degradation with a parabolic dose-response curve, similar to PIF, as 
described [4], with maximal effects as 0.05 and 0.5M respectively.  Protein 
degradation was significantly enhanced in myotubes expressing constitutively 
active Akt, while protein degradation was completely attenuated in myotubes 
expressing dominant negative Akt. 
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 As anticipated myotubes expressing Myr Akt showed a significant 
increase in protein synthesis over wild-type cells (Fig. 2), while myotubes 
expressing DNAkt showed a significant reduction in protein synthesis.  Myotubes 
exposed to PIF showed a reduction in protein synthesis with a maximal effect at 
4.2nM (Fig. 2) as for the effect on protein degradation (Fig. 1B).  However, there 
was no difference in the relative inhibition of protein synthesis in wild-type 
myotubes or in those expressing Myr Akt or DNAkt.  This suggests that Akt is 
unable to reverse the depression in protein synthesis by PIF. 
 The effect on total protein degradation was mirrored by the effect on the 
‘chymotrypsin-like’ enzyme activity, the predominant proteolytic activity of the 
proteasome.  Thus proteolytic activity in the presence of PIF (Fig. 3A), Ang I (Fig. 
3B) Ang II (Fig. 3C) was elevated in myotubes expressing Myr Akt over wild-
type, while there was no increase in activity in myotubes expressing DN-Akt.  In 
addition expression of both 20S proteasome -subunits (Fig. 4A) and p42, an 
ATPase subunit of the 19S regulator (Fig. 4B) in the presence of Ang II showed 
a greater enhancement in myotubes expressing Myr-Akt over wild-type, while 
there was no increase in expression in myotubes expressing DN-Akt.  Levels of 
myosin were also significantly reduced more in myotubes expressing Myr-Akt 
than in wild-type (Fig. 4C), while there was no decrease in myosin in the 
presence of Ang II, when the myotubes expressed DN-Akt.  Thus instead of 
protecting myofibrillar proteins from degradation in the presence of catabolic 
stimuli, Akt appears to be essential for the degradative process and for induction 
of proteasome activity. 
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 To investigate the mechanism of this effect myotubes were incubated with 
PIF and the effect on Akt phosphorylation at Ser473 was determined by 
immunoblotting.  PIF increased Akt phosphorylation 2.5-fold within 30min of 
addition (Fig. 5A), with no effect on the total Akt in the cell (Fig. 5B).  The 
maximal effect was seen at 4.2nM PIF, as with protein degradation (Fig.1B) and 
‘chymotrypsin-like’ enzyme activity (Fig. 3A).  The effect of PIF on Akt 
phosphorylation was completely inhibited by co-treatment with a 2-(4-
morpholinyl)-8-phenyl-4H-I-benzopyran-4-one (LY294002), an inhibitor of PI3-K 
[28], suggesting that Akt activation occurs through a similar mechanism to growth 
factors and cytokines.  The effect of PIF on the chymotrypsin-like enzyme activity 
was also attenuated by LY294002 (Fig. 6A) suggesting that PI3-K is also 
important in the induction of proteasome activity.  LY294002 also attenuated the 
induction of proteasome expression by 15-HETE, considered to be a major signal 
transducer molecule in the induction of proteasome activity by PIF [17] (Fig. 6B).  
These results suggest that activation of PI3-K by PIF occurs downstream of the 
formation of 15-HETE. 
 To investigate the possibility that activated Akt was responsible for the 
phosphorylation and the consequent degradation of I-B, the effect of 
LY294002 on this process was determined.  PIF induced an increase in I-B 
phosphorylation (Fig. 7A) and a reciprocal decrease in the cytosolic level of I-
B in myotubes (Fig. 7B), and this was completely attenuated by LY294002.  
These results suggest that activation of Akt by PIF results in the phosphorylation 
and subsequent degradation of I-B.  The decrease in cytosolic I-B induced 
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by 15(S)-HETE was also attenuated by LY294002 (Fig. 7D).  Degradation of I-
B should result in an increased nuclear accumulation of NF-B and the EMSA 
is shown in Fig. 8.  Thus PIF induced an increased nuclear binding of NF-B, 
with a similar dose-response curve to that for the induction of the degradation of 
I-B (Fig. 7B), and this effect was also completely attenuated by LY294002.  
Thus activation of PI3-K by PIF results in the activation of NF-B.   
Activation of Akt inhibits the ability of tuberous sclerosis complex 2 (TSC2) 
to act as a Rheb-GTPase activating protein (GAP), allowing Rheb-GTP levels to 
rise causing activation of the mammalian target of rapamycin (mTOR). This has 
two primary downstream targets, the ribosomal S6 kinase (p70S6K) and the 
eukaryotic initiation factor 4E (e1F-4E) binding protein, phosphorylation of which 
leads to accelerated protein synthesis [29]. To determine whether this pathway 
was important in protein degradation myotubes were treated with the mTOR 
inhibitor rapamycin (25ng/ml), either before, or at various times after the addition 
of Ang II (Fig 9). Addition of rapamycin, either before, or up to 1h after addition of 
Ang II, completely attenuated the induction of protein degradation, whereas 
addition at later times had no effect. These results suggest that the PI3-
K/Akt/mTOR pathway may be important for the synthesis of proteasome 
subunits, ubiquitin and ubiquitin ligase (E3) involved in the degradation of 
myofibrillar proteins. 
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DISCUSSION 
 The results of this study suggest that contrary to expectations, Akt is 
required for the induction of protein degradation through the ubiquitin-
proteasome pathway by PIF and by Ang I and II.  The mechanism of this effect 
appears to be through increased phosphorylation and subsequent degradation of 
I-B, leading to increased nuclear accumulation of NF-B, which has been 
shown to act as a transcription factor for the induction of proteasome expression 
by both PIF [7] and Ang II [8].  Activation of Akt appears to occur through the 
PI3-K pathway, which is known to be activated by receptor and non-receptor 
tyrosine kinase [30].  This may be a potential mechanism by which PIF could 
activate PI3-K, since the tyrosine kinase inhibitors genistein and tryphostin 23 
have been shown to attenuate PIF-induced proteasome expression [31].  Akt has 
previously only been considered to be involved in muscle hypertrophy and 
inhibition of Akt either by inhibition of PI3-K, or expression of a dominant 
negative Akt reduces the mean size of myotubes in culture [22].  Certainly in this 
study expression of DN-Akt significantly reduced protein synthesis compared 
with wild-type myotubes, whereas expression of constitutively active Akt slightly 
increased protein synthesis, although it did not protect against the fall in protein 
synthesis in the presence of PIF.  Activation of Akt would be expected to inhibit 
atrogin-1 expression through phosphorylation and inactivation of Foxo 
transcription factors [14].  However, muscle atrophy can occur in the absence of 
an increased expression of this E3 ligase, since levels were normal in muscles of 
mice with activated IKK, despite profound muscle wasting [11].  Instead 
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expression of MURF1 was increased, suggesting that it is not necessary to have 
increased expression of both E3 ligases to support an increased protein 
degradation. 
 Activation of Akt appears to be necessary not only for the activation of the 
transcription factor NF-B, leading to increased mRNA levels for proteasome 
subunits and MuRF1 [11], but also for the subsequent protein synthesis, possibly 
through the mTOR/p70S6K pathway. Rapamycin, a specific inhibitor of mTOR 
attenuated the increased protein degradation induced by Ang II when added 
before or up to 1h after the agonist suggesting  a need for the mTOR pathway. 
Thus Akt may play a dual role in the activation of the ubiquitin-proteasome 
pathway. 
 Activation of Akt may provide an alternative pathway from PKC for the 
phosphorylation and degradation of I-Band the nuclear accumulation of NF-
B.  Alternatively there may be some cross-talk between the pathways, since 
PKC-dependent Akt phosphorylation has been reported in JB6 [32] and MCF-7 
cells [33], although in A549 and HEK293 cells PI-3K / Akt signalling is regulated 
by PKC in a negative manner [34].  Studies on interleukin-1 (IL-1)-induced cell 
proliferation have also suggested that the PLC-PKC cascade is required for the 
activation of Erk and Akt signalling [35].  Phosphorylation of other substrates in 
the muscle cell by PKC or Akt may influence the overall outcome of the stimulus.  
It is evident that even stimulation of the same pathway may lead to different 
outcomes.  Thus PI3-K has been shown to activate IKK, IKK and NF-B-
inducing kinase (NIK) by IGF II in the IGF-II dependent myoblast differentiation 
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process [36].  There may also be differences in the sequence of events.  Thus 
LY294002 has been shown to specifically inhibit degradation of I-B in 
RAW264.7 cells, stimulated with interferon- (IFN-), inhibiting the activation of 
NF-B [37].  Other results have suggested that NF-B is required for TNF--
mediated Akt activation and that this lies upstream of the stimulation of Akt [38]. 
 The results of the present study confirm the importance of NF-kB 
activation in the stimulation of protein degradation in murine myotubes and 
provide evidence for an alternative role for Akt in this process. Akt may play a 
dual role in controlling muscle size, depending on the prevailing conditions. 
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Fig. 1 (A)  Western blot of immunoprecipitated HA-tagged Akt in wild-type (lane 
1), DNAkt (lane 2) and Myr Akt (lane 3) using rabbit polyclonal antisera to 
Akt.  The lower band is the Ig light chain.  (B)  Effect of various 
concentrations of PIF (B), Ang I (C) or Ang II (D) on total protein 
degradation in murine myotubes containing wild-type Akt ().  Myr Akt 
() or DNAkt ().  Differences from control are shown as a, p<0.05, b, 
p<0.01 or c, p<0.001, while differences from wild-type are shown as d, 
p<0.05, e, p<0.01 or f, p<0.001.  All experiments were repeated at least 3-
times. 
 
Fig. 2 Effect of PIF on protein synthesis after 4h incubation in myotubes 
containing wild-type Akt (), Myr Akt (   ) and DNAkt ().  Differences 
from controls are indicated as a, p<0.05, while differences from wild-type 
are shown as d, p<0.05 or e, p<0.01. 
 
Fig. 3 The effect of PIF (A), Ang I (B) or Ang II (C) on the 20S proteasome 
chymotrypsin-like enzyme activity in wild-type Akt (), Myr Akt () or 
DNAkt () containing myotubes after 24h incubation.  Differences from 
control are shown as a, p<0.05 or c, p<0.001, while differences from wild-
type are indicated as e, p<0.01 or f, p<0.001. 
 
Fig. 4 Expression of 20S proteasome -subunits (A), p42 (B) and myosin (C) in 
myotubes containing wild-type Akt (), MyrAkt (   ) and DNAkt () in 
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response to Ang II.  An actin loading control is shown in (D).  A 
densitometric analysis representing the average from three blots is shown 
underneath.  Differences from control are shown as c, p<0.001, while 
differences from wild-type are shown as e, p<0.01 or f, p<0.001. 
 
Fig. 5 (A)  Western blots for the effect of PIF on phosphorylation of Akt and (B) 
for total cellular Akt.  Myotubes were treated with for 30min in the absence 
or presence of 100M LY294002 added 2h prior to PIF.  The blots shown 
are representative of three separate experiments.  The densitometric 
analysis is shown below the blot for the phospho Akt for myotubes in the 
absence () or presence (   ) of 100M LY294002.  Differences from 
control in the absence of PIF are shown as c, p<0.001, while differences in 
the presence of LY294002 are indicated as f, p<0.001.  There was no 
difference in the level of total Akt in the cell for any of the treatments. 
 
Fig. 6 (A)  Effect of LY294002 (100M) on the PIF-induced increase in 
‘chymotrypsin-like’ enzyme activity in murine myotubes after 24h 
incubation.  Myotubes were pre-incubated with LY294002 () or no-
treatment (X) 2h prior to the addition of PIF.  (B)  Effect of LY294002 
(100M) on the 15(S)-HETE induced increase in ‘chymotrypsin-like’ 
enzyme activity in murine myotubes after 24h incubation.  Myotubes were 
pre-incubated with LY294002 () or no-treatment (X) 2h prior to the 
addition of 15(S)-HETE.  Differences from control are indicated as a, 
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p<0.05, b, p<0.01, or c, p<0.001, while differences in the presence of 
LY294002 are indicated as d, p<0.05 and f, p<0.001.  Both experiments 
were repeated three times (n=9). 
 
Fig. 7 Western blot for the effect of PIF on phospho I-B (A), I-B(B) and 
total cellular actin (C) determined 30min after addition of PIF.  Myotubes 
were treated with 0 in the absence or presence of 100M LY294002.  The 
blots shown are representative of the three separate experiments.  The 
densitometric analysis is shown below each blot for myotubes in the 
absence () or presence (   ) of LY294002.  Differences from control are 
shown as a, p<0.05, b, p<0.01 or c, p<0.001, while differences in the 
presence of LY294002 are shown as d, p<0.05, e, p<0.01 or f, p<0.001.  A 
Western blot for I-Bin myotubes 30min after treatment with 15(S)-
HETE is shown in (D), while the actin loading control is shown in (E).  
Myotubes were treated for 30min with 0 15(S)-HETE in the absence or 
presence of 100M LY294002.  The densitometric analysis is the average 
of three replicate blots for myotubes in the absence (solid boxes) or 
presence (hatched boxes) of LY294002.  Differences from control are 
indicated as c, p<0.001, while differences in the presence of LY294002 
are shown as f, p<0.001. 
 
Fig. 8 Effect of PIF on the nuclear translocation of NF-B in murine myotubes as 
determined by EMSA, in the absence (lanes 1-5) or presence (lanes 6-10) 
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of 100M LY294002.  Myotubes were treated for 30min with 0 (lanes 1 
and 6), 2.1 (lanes 2 and 7), 4.2 (lanes 3 and 8), 10.5 (lanes 5 and 9) or 
16.8nM PIF (lanes 5 and 10).  Lane 11 is a positive control for NF-B and 
lane 12 is the positive control in the presence of a 100-fold excess of 
unlabelled NF-B probe.  The densitometric analysis is an average of 
three replicate EMSA’s.  Differences from control are indicated as b, 
p<0.01 and c, p<0.001, while differences in the presence of LY294002 are 
shown as f, p<0.001. 
 
Fig. 9 Effect of Ang II on total protein degradation in murine myotubes in the 
absence () or presence of rapamycin (25ng/ml) added either before () 
(A) or at 30min(x), 1h(), 2h() or 4h( ) after Ang II (B). Differences from 
control are indicated as b, p<0.01 and c, p<0.001, while differences from 
Ang II alone are shown as f, p<0.001. 
 
